By Brad Sorensen, CFA
NASDAQ:REVB
READ THE FULL REVB RESEARCH REPORT
Revelation Biosciences (NASDAQ:REVB) begins 2026 with great momentum and making decisions that put commercialization of its important treatment in reach. We believe this year will be a transformational one for the company and suggest investors take a look at REVB before the inflection point we believe is coming.
Gemini is the company’s primary treatment and is an intravenously administered treatment that reduces the damage associated with inflammation, which could be used in treating numerous conditions. Gemini is currently in a Phase 1b trial for chronic kidney disease (CKD), which approximately 37 million people are afflicted with. The company recently released data from its Phase 1 PRIME clinical study in stage 3 and 4 CKD patients. The primary endpoint to evaluate safety and tolerability of escalating doses was met.
But the major news was that Gemini reduced inflammatory activity and restored normal cellular response. This demonstrates Gemini’s ability to durably rebalance the inflammatory process at the cellular level. This has implications for dozens of afflictions, such as CKD and burns, and makes the process toward commercialization more likely in our view. The statement from the Principal Investigator made us take additional notice as it was more positive than what we have often seen. Dr. Pablo Pergola, Research Director at Clinical Advancement Center, PLLC., noted, “The activity observed with a single dose of Gemini in patients is shocking. This effect suggests a meaningful step forward in addressing the underlying immune dysregulation observed in patients with chronic kidney disease, and I am intrigued by the potential of Gemini to treat multiple types of acute and chronic inflammation.”
Specifically, test results showed that in patients with high background PBMC activity, which are immune cells and can help be a measure of inflammation, Gemini significantly reduced inflammation relative to placebo patient PBMCs post dose and remained significantly below their baseline value through 7 days. Background inflammation was reduced to levels comparable to PBMCs isolated from healthy subjects. The importance of this cannot be overstated. Gemini is changing the cells and returning them to a normal state from the inflamed state, which treats the patient durably instead of just masking the symptoms. This ability has the potential to positively affect millions of patients suffering from CKD and other inflammatory diseases in a way that has been impossible to this point.
Earlier this year, the company announced that it is starting the GMP manufacturing of Gemini and the placebo. We view this as a very positive step that shows management’s confidence in the need for more product for later-stage testing and will avoid delays as those tests begin. Additionally, the company announced that it is presenting the above referenced results to The International Conference on Advances in Critical Care Nephrology—another indication of the traction that REVB is getting.
We are under no illusions that it’s easy to bring new therapies all the way to commercialization, but view these results as a significant step forward to that goal. As a result, we recently raised our price target on REVB to $22.50 per share and urge investors to use this groundbreaking news to consider investing in REVB.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.